Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Therapeutic-equivalence Study Comparing The Efficacy And Safety Of Intravenous Epoetin Hospira And Epoetin Alfa (Amgen) In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment

NCT01473407 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01473407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01473407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Therapeutic-equivalence Study Comparing The Efficacy And Safety Of Intravenous Epoetin Hospira And Epoetin Alfa (Amgen) In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
February 11, 2014
Enrollment
612 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, chronic renal failure